Riskpilot← Back to searchSign inGet full accessKJ Bio A/S
A/SDissolvedCVR 40352104Skanderborgvej 193Research and experimental development on natural sciences and engineering · NACE 7210Est. 20191 employees
Revenue 2024
DKK -52K
-62% vs 2023
EBITDA margin
136.1%
+88% vs 2023
Equity ratio
-25001.6%
Financial strength
Net profit 2024
DKK -107K
+81% vs 2023
| Revenue | DKK -52K | -62% |
| EBITDA | DKK -70K | +88% |
| Net profit | DKK -107K | +81% |
| Total assets | DKK 2K | -99% |
| Equity | DKK -608K | -21% |
| Employees | 1 | — |
Legal name
KJ Bio A/S
CVR number
40352104
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8. marts 2019
Share capital
DKK 400.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren og bestyrelsesformanden i forening eller af den samlede bestyrelse.
Address
Skanderborgvej 193
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -903 | 262 | -123 | -135 | -52 |
| Staff expenses | -747 | -1.212 | -170 | -467 | -19 |
| EBITDA | -1.650 | -950 | -292 | -602 | -70 |
| Depreciation & amort. | -249 | -2.498 | -225 | -125 | -0 |
| EBIT | -1.899 | -3.448 | -517 | -727 | -70 |
| Net financials | -5 | -6 | -8 | -19 | -38 |
| Profit before tax | -1.904 | -3.453 | -526 | -747 | -107 |
| Tax | -0 | -0 | -0 | -187 | -1 |
| Net profit | -1.904 | -3.453 | -526 | -560 | -107 |
| Item | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3.621 | 883 | 194 | 223 | 2 |
| Equity | -1.504 | 585 | 59 | -501 | -608 |
| Long-term debt | 4.920 | 84 | 0 | 0 | 0 |
| Short-term debt | 205 | 214 | 135 | 724 | 610 |
| Total debt | 5.125 | 299 | 135 | 724 | 610 |
EBITDA margin
-7032000.0%
This company
15.8%
Market median
-44506429% vs market
20192024
Equity ratio
-25001.6%
This company
38.2%
Market median
-65549% vs market
20192024
Return on equity
-10652100.0%
This company
18.4%
Market median
-57891948% vs market
20192024
Net profit margin
-10652100.0%
This company
8.1%
Market median
-131507507% vs market
20192024
Asset turnover
-21.26×
This company
1.12×
Market median
-1998% vs market
20192024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-01-01 – 2021-04-30
- Annual report 2019Filed via CVR / Virk · Period 2019-03-08 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SP Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
A/S KNUD JEPSEN | Company | 100.0% | 100.0% | 2021 |
| Individual | 50.0% | 50.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KJ Bio A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Søren Peter Korup | Chief Executive Officer | 0 companies |
| Frands Nørgaard Jepsen | Chairman | 0 companies |
| Morten Petersen | Board of Directors | 0 companies |
| Brian David Athaide | Chairman | 0 companies |
| Louise Brinch Jepsen | Board of Directors | 0 companies |
| Anna Stewart | Board of Directors | 0 companies |